Liisa Bayko
Stock Analyst at Evercore ISI Group
(4.42)
# 282
Out of 4,784 analysts
83
Total ratings
51.47%
Success rate
21.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liisa Bayko
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Upgrades: Outperform | $60 → $99 | $36.99 | +167.64% | 2 | Feb 14, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $33 → $45 | $19.68 | +128.66% | 5 | Feb 12, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $10 → $12 | $7.86 | +52.67% | 5 | Jan 13, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $7 → $5 | $1.25 | +300.00% | 5 | Dec 16, 2024 | |
| CARM Carisma Therapeutics | Downgrades: In-Line | $4 → $0.7 | $0.33 | +112.12% | 2 | Dec 11, 2024 | |
| SVRA Savara | Downgrades: In-Line | $7 → $5 | $2.91 | +71.82% | 3 | Nov 13, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $30 → $35 | $23.09 | +51.58% | 4 | Oct 30, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $405 → $360 | $327.87 | +9.80% | 9 | Aug 8, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $210 → $260 | $268.46 | -3.15% | 1 | Jun 25, 2024 | |
| AVTE Aerovate Therapeutics | Downgrades: In-Line | $27 → $2 | $2.53 | -20.95% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $2 | $1.39 | +43.88% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $33 | $8.08 | +308.42% | 4 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $38 | $42.72 | -11.05% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $438 | $492.69 | -11.10% | 17 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $80 | $37.82 | +111.53% | 8 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $5.70 | +215.79% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $25 | $5.32 | +369.92% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $62 | $5.71 | +985.81% | 4 | Jul 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $6.34 | +452.05% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $24 | $26.63 | -9.88% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $30 | $9.23 | +225.03% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $10 | $3.50 | +185.71% | 1 | Feb 5, 2020 |
CRISPR Therapeutics AG
Feb 14, 2025
Upgrades: Outperform
Price Target: $60 → $99
Current: $36.99
Upside: +167.64%
Travere Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $33 → $45
Current: $19.68
Upside: +128.66%
BioCryst Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $10 → $12
Current: $7.86
Upside: +52.67%
Editas Medicine
Dec 16, 2024
Maintains: Outperform
Price Target: $7 → $5
Current: $1.25
Upside: +300.00%
Carisma Therapeutics
Dec 11, 2024
Downgrades: In-Line
Price Target: $4 → $0.7
Current: $0.33
Upside: +112.12%
Savara
Nov 13, 2024
Downgrades: In-Line
Price Target: $7 → $5
Current: $2.91
Upside: +71.82%
Kiniksa Pharmaceuticals International,
Oct 30, 2024
Maintains: Outperform
Price Target: $30 → $35
Current: $23.09
Upside: +51.58%
Madrigal Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $405 → $360
Current: $327.87
Upside: +9.80%
Alnylam Pharmaceuticals
Jun 25, 2024
Maintains: Outperform
Price Target: $210 → $260
Current: $268.46
Upside: -3.15%
Aerovate Therapeutics
Jun 18, 2024
Downgrades: In-Line
Price Target: $27 → $2
Current: $2.53
Upside: -20.95%
May 16, 2024
Maintains: In-Line
Price Target: $7 → $2
Current: $1.39
Upside: +43.88%
May 15, 2024
Maintains: Outperform
Price Target: $37 → $33
Current: $8.08
Upside: +308.42%
May 15, 2024
Maintains: Outperform
Price Target: $50 → $38
Current: $42.72
Upside: -11.05%
Apr 11, 2024
Upgrades: Outperform
Price Target: $438
Current: $492.69
Upside: -11.10%
Jun 6, 2023
Upgrades: Outperform
Price Target: $60 → $80
Current: $37.82
Upside: +111.53%
Mar 28, 2023
Initiates: Outperform
Price Target: $18
Current: $5.70
Upside: +215.79%
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $5.32
Upside: +369.92%
Jul 6, 2022
Upgrades: Outperform
Price Target: $62
Current: $5.71
Upside: +985.81%
Nov 23, 2021
Initiates: Outperform
Price Target: $35
Current: $6.34
Upside: +452.05%
Jun 8, 2021
Initiates: Outperform
Price Target: $24
Current: $26.63
Upside: -9.88%
Nov 24, 2020
Reinstates: Outperform
Price Target: $30
Current: $9.23
Upside: +225.03%
Feb 5, 2020
Upgrades: Market Outperform
Price Target: $10
Current: $3.50
Upside: +185.71%